BR-1733

Main objectives Phase I (dose escalation phase) 1. Evaluate the safety and tolerability of BR1733 monotherapy for advanced malignant tumors, and determine the maximum tolerated dose (MTD) and/or the recommended dose for Phase II clinical trials (RP2D, Recommended Phase II Dose); Phase II (dose expansion phase) 2. Evaluate the effectiveness of BR1733 monotherapy for advanced malignant tumors (solid tumors are evaluated according to the solid tumor evaluation criteria RECIST V1.1, see Appendix 1; non-Hodgkin's lymphoma is evaluated according to the 2014 version of Lugano evaluation criteria, see Appendix 2). Secondary objectives 1. Evaluate the pharmacokinetic (PK) characteristics of BR1733; 2. Evaluate the pharmacodynamic (PD) characteristics of BR1733. Exploratory purpose 3. To explore the relationship between EZH2/EED mutation status and/or expression and the anti-tumor efficacy of BR1733; 4. To explore the relationship between BR1733 exposure and efficacy, safety and PD indicators.